drugset

drugset / Trial / NCT06816108

A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

NCT06816108 ↗

Phase 1 Recruiting 60 enrolled Ono Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the tolerability and safety of ONO-7428 in participants with unresectable advanced or recurrent solid tumors.

Timeline

Start: 2025-04-21
Primary completion: 2029-07
Completion: 2029-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ONO-7428	Unknown	—	—

Indications